DOSAGE AND ADMINISTRATION
An identical dosage regimen may be followed by administering AMICAR Tablets or AMICAR Oral Solution as follows:

For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR 1000 mg Tablets or 10 AMICAR 500 mg Tablets (5 g) or 20 milliliters of AMICAR Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR 1000 mg Tablet or 2 AMICAR 500 mg Tablets (1 g) or 5 milliliters of AMICAR Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled.

HOW SUPPLIED:
AMICAR® (aminocaproic acid)

AMICAR Oral Solution, 0.25 g/mL
Each mL of raspberry-flavored oral solution contains 0.25 g/mL of aminocaproic acid.
8 Fl. Oz. (236.5 mL) Bottle – NDC 49411-052-08
Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature]; Dispense in Tight Containers; Do Not Freeze.

AMICAR 500 mg Tablets
Each round, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 10 on the right, contains 500 mg of aminocaproic acid.
Bottle of 30 – NDC 49411-050-30
Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature]; Dispense in Tight Containers; Do Not Freeze.

AMICAR 1000 mg Tablets
Each oblong, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 20 on the
right, contains 1000 mg of aminocaproic acid.
Bottle of 30 – NDC 49411-051-30
Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature]; Dispense in Tight Containers; Do Not Freeze.